Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Queensland Health
Farmers Insurance
Covington
Cipla
Daiichi Sankyo
QuintilesIMS
Federal Trade Commission
Novartis
Cantor Fitzgerald

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,716,867

« Back to Dashboard

Which drugs does patent 6,716,867 protect, and when does it expire?

Patent 6,716,867 protects PRECEDEX and is included in one NDA.

Protection for PRECEDEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in twenty-seven countries.
Summary for Patent: 6,716,867
Title: Use of dexmedetomidine for ICU sedation
Abstract:The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
Inventor(s): Aantaa; Riku (Turku, FI), Bachand; Romeo (Mundelain, IL), Heinonen; Esa (Turku, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/647,364
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 6,716,867

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-004 Nov 14, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-001 Dec 17, 1999 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-002 Mar 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-003 Mar 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,716,867

PCT Information
PCT FiledMarch 31, 1999PCT Application Number:PCT/FI99/00266
PCT Publication Date:October 07, 1999PCT Publication Number: WO99/49854

International Patents Family Members for US Patent 6,716,867

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 015744 ➤ Sign Up
Austria 347359 ➤ Sign Up
Australia 3149499 ➤ Sign Up
Australia 754484 ➤ Sign Up
Bulgaria 104797 ➤ Sign Up
Bulgaria 64540 ➤ Sign Up
Brazil 9909872 ➤ Sign Up
Canada 2326339 ➤ Sign Up
China 1168441 ➤ Sign Up
China 1295473 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
US Army
Federal Trade Commission
Merck
Covington
Fish and Richardson
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot